RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations
RLY-4008，首个对FGFR2改变和耐药突变均具有活性的高选择性FGFR2抑制剂
期刊:Cancer Discovery
影响因子:29.7
doi:10.1158/2159-8290.CD-23-0475
Vivek Subbiah #,Vaibhav Sahai #,Dejan Maglic,Kamil Bruderek,B Barry Touré #,Songping Zhao,Roberto Valverde,Patrick J O'Hearn,Demetri T Moustakas,Heike Schönherr,Nastaran Gerami-Moayed,Alexander M Taylor,Brandi M Hudson #,Damian J Houde,Debjani Pal,Lindsey Foster,Hakan Gunaydin,Pelin Ayaz,Dina A Sharon #,Lipika Goyal #,Alison M Schram,Suneel Kamath,Cori Ann Sherwin,Oleg Schmidt-Kittler,Kai Yu Jen,Fabien Ricard,Beni B Wolf,David E Shaw,Donald A Bergstrom,James Watters,Jessica B Casaletto
